Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways

Journal of Surgical Research

Volumn 184, Issue 2, 2013, Pages 898-906

  Kandil, Emad ^a   Tsumagari, Koji ^a   Ma, Jingjing ^a   Abd Elmageed, Zakaria Y ^a   Li, Xinying ^a,b   Slakey, Douglas ^a   Mondal, Debasis ^a   Abdel Mageed, Asim B ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

AZD6244; GDC0941; MAPK; PI3K AKT; Synergism; Thyroid cancer

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; SELUMETINIB;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER; WESTERN BLOTTING;

AZD6244; GDC0941; MAPK; PI3K/AKT; SYNERGISM; THYROID CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; INDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SULFONAMIDES; THYROID NEOPLASMS;

EID: 84883859793     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.03.052     Document Type: Article

References (41)

1. L. Davies, and H.G. Welch Increasing incidence of thyroid cancer in the United States, 1973-2002 JAMA 295 2006 2164
2. L. Leenhardt, P. Grosclaude, and L. Cherie-Challine Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee Thyroid 14 2004 1056
3. E.L. Mazzaferri An overview of the management of thyroid cancer E.L. Mazzaferri, C. Harmer, U.K. Mallick, P. Kendall-Taylor, Practical management of thyroid cancer: a multidisciplinary approach 2006 Springer-Verlag London, England 1 28
4. Altekruse SF, Kosary CF, Krapcho M, et al, editors. SEER cancer statistics review, 1975-2007, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975-2007/. Accessed November 2012
5. Y. Lalami, and A. Awada Recurrent thyroid cancer: a molecular-based therapeutic breakthrough Curr Opin Oncol 23 2011 235
6. P. Kundra, and K.D. Burman Thyroid cancer molecular signaling pathways and use of targeted therapy Endocrinol Metab Clin North Am 36 2007 839
7. Y.C. Henderson, Y. Chen, and M.J. Frederick MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo Mol Cancer Ther 9 2010 1968
8. D. Liu, Z. Liu, D. Jiang, A.P. Dackiw, and M. Xing Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations J Clin Endocrinol Metab 92 2007 4686
9. A.L. Ho, and E. Sherman Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer Clin Adv Hematol Oncol 9 2011 32
10. V. Gupta-Abramson, A.B. Troxel, and A. Nellore Phase II trial of sorafenib in advanced thyroid cancer J Clin Oncol 26 2008 4714
11. R. Liu, D. Liu, and E. Trink The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway J Clin Endocrinol Metab 96 2011 E577
12. F. Furuya, C. Lu, M.C. Willingham, and S.Y. Cheng Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer Carcinogenesis 28 2007 2451
13. M. Mandal, S. Kim, and M.N. Younes The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells Br J Cancer 92 2005 1899
14. D. Liu, and M. Xing Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways Thyroid 18 2008 853
15. D. Brzezianska, and D. Pastuszak-Lewandoska A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm Front Biosci 16 2011 422
16. G. Garcia-Rostan, A.M. Costa, and I. Pereira-Castro Mutation of the PIK3CA gene in anaplastic thyroid cancer Cancer Res 65 2005 10199
17. P. Hou, D. Liu, and Y. Shan Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer Clin Cancer Res 13 2007 1161
18. L. Santarpia, A.K. El-Naggar, G.J. Cote, J.N. Myers, and S.I. Sherman Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer J Clin Endocrinol Metab 93 2008 278
19. R. Leboeuf, J.E. Baumgartner, and M. Benezra BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines J Clin Endocrinol Metab 93 2008 2194
20. M. Kohno, and J. Pouyssegur Targeting the ERK signaling pathway in cancer therapy Ann Med 38 2006 200
21. U. Banerji, D.R. Camidge, and H.M. Verheul The first -in-human study of the hydrogen sulfate (Hyd- sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer Clin Cancer Res 16 2010 1613
22. L. Salphati, H. Wong, and M. Belvin Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941 Drug Metab Dispos 38 2010 1436
23. F.I. Raynaud, S.A. Eccles, and S. Patel Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 Mol Cancer Ther 8 2009 1725
24. C. O'Brien, J.J. Wallin, and D. Sampath Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models Clin Cancer Res 16 2010 3670
25. D. Liu, P. Hou, and Z. Liu Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin Cancer Res 69 2009 7311
26. S. Welkos, and A. O'Brien Determination of median lethal and infectious doses in animal model systems Methods Enzymol 235 1994 29
27. T. Hideshima, J.E. Bradner, and J. Wong Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc Natl Acad Sci U S A 102 2005 8567
28. D. Liu, J. Xing, B. Trink, and M. Xing BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus Int J Cancer 127 2010 2965
29. R. Liu, D. Liu, and M. Xing The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAFV600E inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells J Clin Endocrinol Metab 97 2012 E173
30. J.A. Fagin Genetics of papillary thyroid cancer initiation: implications for therapy Trans Am Clin Climatol Assoc 116 2005 259 discussion 269
31. M. Xing BRAF mutation in thyroid cancer Endocr Relat Cancer 12 2005 245
32. D. Liu, Z. Liu, S. Condouris, and M. Xing BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells J Clin Endocrinol Metab 92 2007 2264
33. G. Salvatore, V. De Falco, and P. Salerno BRAF is a therapeutic target in aggressive thyroid carcinoma Clin Cancer Res 12 2006 1623
34. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291
35. D.W. Ball, N. Jin, and D.M. Rosen Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 J Clin Endocrinol Metab 92 2007 4712
36. E.E. Cohen, L.S. Rosen, and E.E. Vokes Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 2008 4708
37. S.I. Sherman, L.J. Wirth, and J.P. Droz Motesanib diphosphate in progressive differentiated thyroid cancer N Engl J Med 359 2008 31
38. Z. Liu, P. Hou, and M. Ji Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers J Clin Endocrinol Metab 93 2008 3106
39. E.A. Kolb, R. Gorlick, and P.J. Houghton Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program Pediatr Blood Cancer 55 2010 668
40. R.E. Board, G. Ellison, and M.C. Orr Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study Br J Cancer 101 2009 1724
41. A.A. Adjei, R.B. Cohen, and W. Franklin Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers J Clin Oncol 26 2008 2139